

Special Issue

Endothelial Dysfunction: From a Pathophysiological Mechanism to a Potential Therapeutic Target—3rd Edition

Message from the Guest Editors

Following the success of the first two volumes of the Special Issue titled "Endothelial Dysfunction: From a Pathophysiological Mechanism to a Potential Therapeutic Target," we are pleased to announce the launch of a third volume. This new edition aims to gather and disseminate the latest cutting-edge research on this vital topic. This Special Issue will focus on the mechanisms, diagnostic approaches, and prognostic and therapeutic implications of endothelial dysfunction as a biomarker of inflammation, oxidative stress, and vascular disease. We welcome submissions that encompass basic and clinical research, as well as omics-based and translational approaches. The issue will include original research articles, reviews, and a limited number of relevant meta-analyses.

Guest Editors

Dr. Pasquale Ambrosino

Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy

Prof. Dr. Guido Grassi

Dipartimento di Medicina Clinica, Università Milano-Bicocca, Ospedale San Gerardo di Monza, Monza, Italy

Deadline for manuscript submissions

28 February 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/218380

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).